Core Insights - Techne (TECH) reported revenue of $286.56 million for the quarter ended September 2025, reflecting a year-over-year decline of 1% and a surprise of -0.96% compared to the Zacks Consensus Estimate of $289.34 million [1] - The earnings per share (EPS) for the same period was $0.42, unchanged from the previous year, indicating no EPS surprise against the consensus estimate [1] Financial Performance Metrics - Organic growth was reported at -1%, contrasting with the estimated growth of 1.1% by analysts [4] - Net Sales in Protein Sciences amounted to $202.2 million, below the average estimate of $208.25 million, representing a year-over-year decline of -1.1% [4] - Net Sales in Diagnostics and Spatial Biology reached $79.5 million, slightly below the average estimate of $80.65 million, showing a year-over-year change of -4.4% [4] Stock Performance - Techne's shares have returned +3.2% over the past month, outperforming the Zacks S&P 500 composite, which saw a +1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Techne (TECH) reported revenue of $316.96 million for the quarter ended June 2025, marking a year-over-year increase of 3.6% and exceeding the Zacks Consensus Estimate of $315.44 million by 0.48% [1] - The company achieved an EPS of $0.53, up from $0.49 a year ago, with a surprise of 6% compared to the consensus estimate of $0.50 [1] Financial Performance Metrics - Organic Growth for the company was reported at 3%, aligning with the three-analyst average estimate of 3% [4] - Organic Growth in Diagnostics and Spatial Biology was -1%, falling short of the estimated 2.3% by two analysts [4] - Organic Growth in Protein Sciences was 4%, surpassing the two-analyst average estimate of 2.7% [4] - Net Sales from intersegment revenue was $0.79 million, significantly better than the average estimate of -$0.5 million, representing a year-over-year change of -225.3% [4] - Net Sales in Protein Sciences reached $226.47 million, exceeding the two-analyst average estimate of $224.65 million, with a year-over-year increase of 5.8% [4] - Net Sales in Diagnostics and Spatial Biology were $89.71 million, below the estimated $92.75 million, reflecting a -1.1% change compared to the previous year [4] Stock Performance - Techne's shares have returned +3.7% over the past month, outperforming the Zacks S&P 500 composite's +0.5% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]